EU – Parliament adopts its position on EU pharmaceutical reform
MEPs adopted their proposals to revamp EU pharmaceutical legislation, to foster innovation and enhance the security of supply, accessibility and affordability of medicines.
The legislative package, covering medicinal products for human use, consists of a new directive (adopted with 495 votes in favour, 57 against and 45 abstentions) and regulation (adopted with 488 votes in favour, 67 against and 34 abstentions).
Incentives for innovation
MEPs want to introduce a minimum regulatory data protection period (during which other companies cannot access product data) of seven and a half years, in addition to two years of market protection (during which generic, hybrid or biosimilar products cannot be sold), following a marketing authorisation.
More information on the European Parliament Website.
OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (4 octobre 2024). EU – Parliament adopts its position on EU pharmaceutical reform. ELSIBI. Consulté le 16 mars 2026 à l’adresse https://doi.org/10.58079/12f6s





